RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Crinetics Pharmaceuticals Stock

Crinetics Pharmaceuticals Employees 2024

Crinetics Pharmaceuticals Employees

68

Ticker

CRNX

ISIN

US22663K1079

WKN

A2JQTJ

In 2024, Crinetics Pharmaceuticals employed 68 people, a 0% change from the 68 number of employees in the previous year.

Crinetics Pharmaceuticals Aktienanalyse

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals Inc. is a leading biopharmaceutical company specializing in the development and commercialization of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company was founded in 2008 by a team of experienced pharmacy professionals and is headquartered in San Diego, California. History Crinetics Pharmaceuticals was founded based on groundbreaking research in the field of endocrine diseases. The company aims to develop innovative therapies for rare endocrine diseases and hormone-dependent tumors that have been inadequately treated thus far. Crinetics draws on decades of experience and in-depth knowledge in the fields of endocrinology, neuroscience, and cancer research. Business model Crinetics is a research and development company specializing in the discovery, development, and commercialization of drugs for rare endocrine diseases. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Different divisions Crinetics specializes in the research, development, and commercialization of products that can be used in rare endocrine diseases and hormone-dependent tumors. The company operates in various areas, including: - Acromegaly: Crinetics is developing a medication for the treatment of acromegaly, a rare disease caused by overproduction of growth hormone. - Cushing's syndrome: Crinetics is developing a medication for the treatment of Cushing's syndrome, a rare disease caused by overproduction of cortisol. - Hypoparathyroidism: Crinetics is developing a medication for the treatment of hypoparathyroidism, a rare disease characterized by insufficient production of parathyroid hormone. - Neuroendocrine tumors: Crinetics is developing a medication for the treatment of neuroendocrine tumors, a rare group of tumors that arise from neuroendocrine cells. Products Crinetics has an extensive portfolio of innovative products based on novel mechanisms of action that are in various stages of development. The company focuses on developing drugs that can be used in rare endocrine diseases and hormone-dependent tumors. Some of the notable products are: - CRN00808: CRN00808 is a medication that can help improve the body's monitoring system that regulates the release of growth hormones. It is currently in phase 2 clinical trials. - CRN01941: CRN01941 is a medication for the treatment of Cushing's syndrome. It has been developed to inhibit excessive production of cortisol and is currently in phase 2 clinical trials. - CRN04777: CRN04777 is a medication for the treatment of acromegaly. It has been developed to inhibit overproduction of growth hormone and is currently in phase 1 clinical trials. - CRN04894: CRN04894 is a medication for the treatment of hypoparathyroidism. It has been developed to stimulate parathyroid hormone production and is currently in phase 1 clinical trials. Conclusion Crinetics Pharmaceuticals is a leading biopharmaceutical company specializing in the development of innovative therapies for rare endocrine diseases and hormone-dependent tumors. The company has an extensive portfolio of proprietary compounds based on novel mechanisms of action that are in various stages of development. Crinetics works closely with leading experts in the field of endocrinology and oncology to develop and commercialize groundbreaking new therapies. Crinetics Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Employees Details

Examining Crinetics Pharmaceuticals's Employee Base

Crinetics Pharmaceuticals's employees are a pivotal aspect of its operations, driving innovation, productivity, and growth. The size and composition of the workforce offer insights into the company's scale, diversity, and investment in human capital. Analyzing employee trends and data is essential for understanding Crinetics Pharmaceuticals's operational capacity and future potential.

Year-to-Year Comparison

Assessing Crinetics Pharmaceuticals's employee numbers year-over-year helps in identifying growth patterns, expansions, or contractions. An increasing employee count can indicate scaling operations and investment in talent, while a decrease may signal efficiency improvements, automation, or business challenges.

Impact on Investments

Crinetics Pharmaceuticals's employee data impacts investment decisions by shedding light on the company’s operational efficiency, innovation capability, and sustainability. Investors assess workforce data to gauge the firm's potential to execute strategies, innovate, and adapt to market changes effectively.

Interpreting Employee Trends

Fluctuations in Crinetics Pharmaceuticals’s employee numbers indicate changes in business strategy, operational demands, and market dynamics. Investors and analysts scrutinize these trends to evaluate the company’s strategic positioning, adaptability, and potential for sustainable growth.

Frequently Asked Questions about Crinetics Pharmaceuticals stock

How many employees does Crinetics Pharmaceuticals have this year?

Crinetics Pharmaceuticals has 68 undefined employees this year.

How many employees did Crinetics Pharmaceuticals have compared to the previous year?

Compared to the previous year, Crinetics Pharmaceuticals had 0% more employees.

What impact did the number of employees have on the company Crinetics Pharmaceuticals?

The number of employees has a direct impact on the efficiency and productivity of Crinetics Pharmaceuticals. A higher number of employees can indicate that the company is growing and has more resources to achieve its goals, while a lower number of employees may suggest that the company is saving costs or facing difficulties in recruiting new employees.

What impact did the number of employees have on investors of Crinetics Pharmaceuticals?

The number of employees can also have an impact on investors of Crinetics Pharmaceuticals, as it can be an indicator of the company's growth and financial health. A higher number of employees can promise investors, while a lower number of employees may raise concerns.

How does an increase in equity capital of Crinetics Pharmaceuticals affect the company?

An increase in equity of Crinetics Pharmaceuticals can improve the financial strength of the company and increase its ability to make future investments and fulfill obligations.

How does a reduction in Crinetics Pharmaceuticals's equity affect the company?

A reduction in equity of Crinetics Pharmaceuticals can impair its financial stability and decrease its ability to fulfill future investments and obligations.

What are some factors that influence the equity of Crinetics Pharmaceuticals?

Some factors that can influence the equity of Crinetics Pharmaceuticals include, among others, revenue development, profit and loss statement, dividend payments, and investments.

Why is the equity of Crinetics Pharmaceuticals so important for investors?

The equity of Crinetics Pharmaceuticals is important for investors as it is an indicator of the company's financial stability and provides investors with information on the amount of financial backing the company has in terms of obligations and future investments.

How does the number of employees at Crinetics Pharmaceuticals influence the company?

The number of employees at Crinetics Pharmaceuticals can directly impact the growth and performance of the company. A higher number of employees can lead to increased capacity and productivity, while a lower number of employees may result in reduced efficiency and limitations.

How has the number of employees at Crinetics Pharmaceuticals evolved in recent years?

In recent years, the number of employees at Crinetics Pharmaceuticals has changed by 0.

How many employees does Crinetics Pharmaceuticals currently have?

Crinetics Pharmaceuticals currently has 68 undefined employees.

Why is the number of employees important for investors of Crinetics Pharmaceuticals?

The number of employees is important for investors of Crinetics Pharmaceuticals as it is an indicator of the growth potential and performance of the company. It also provides information on how the company is able to manage and recruit its workforce.

What strategic measures can Crinetics Pharmaceuticals take to change the number of employees?

To change the number of employees, Crinetics Pharmaceuticals can take various measures such as adjusting compensation packages, improving working conditions, conducting recruitment campaigns, and promoting a positive corporate culture. It is important for the company to conduct a thorough assessment of its situation to determine the best strategic actions to change its number of employees.

How much dividend does Crinetics Pharmaceuticals pay?

Over the past 12 months, Crinetics Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Crinetics Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Crinetics Pharmaceuticals?

The current dividend yield of Crinetics Pharmaceuticals is .

When does Crinetics Pharmaceuticals pay dividends?

Crinetics Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Crinetics Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Crinetics Pharmaceuticals located?

Crinetics Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Crinetics Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Crinetics Pharmaceuticals from 9/21/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/21/2024.

When did Crinetics Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/21/2024.

What was the dividend of Crinetics Pharmaceuticals in the year 2023?

In the year 2023, Crinetics Pharmaceuticals distributed 0 USD as dividends.

In which currency does Crinetics Pharmaceuticals pay out the dividend?

The dividends of Crinetics Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Crinetics Pharmaceuticals

Our stock analysis for Crinetics Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Crinetics Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.